BLPH

Bellerophon Therapeutics

Last Updated:

Q3 2020

Price

quotes and stock data delayed 15 minutes

Cash

$54M

Burn Rate (Qtr)

$7.9M

Company Profile

We are a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. We are currently developing three product candidates under our INOpulse platform, a proprietary pulsatile nitric oxide drug delivery system. The first is for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The second product candidate is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third is for the treatment of pulmonary hypertension associated with sarcoidosis (PH-Sarc). All three of our programs are in Phase 2 development.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

INOpulse® | COViNOX

COVID-19

Phase 3 (Data)

TBA

INOpulse

PH-COPD

Phase 3

TBD

INOpulse

PH-ILD

Phase 2

TBD

INOpulse

PH-Sarc

Phase 2

TBD

Recent Posts

See what the community is saying - click to see full post

BLPH - Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® fo

BLPH - Phase 2/3 Publication of Data in CHEST Journal

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon